ORKEPA
Live / Applied — Fifth extension granted (statement of use) (as of 05 Feb 2026)
What this means for you
Not registered yet, but its 19 Nov 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97134752
- Mark type
- Stylized text
- Filed
- 19 Nov 2021
- Published for opposition
- 04 Apr 2023
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 05 Feb 2026 — SOU EXTENSION 5 GRANTED
- 04 Nov 2025 — SOU EXTENSION 5 FILED
- 05 Feb 2026 — ITU LETTER MAILED, NO RESPONSE REQUIRED
- 26 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 May 2025 — SOU EXTENSION 4 GRANTED
- 05 May 2025 — SOU EXTENSION 4 FILED
- 05 May 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Nov 2024 — SOU EXTENSION 3 GRANTED
- 07 Nov 2024 — SOU EXTENSION 3 FILED
- 07 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 06 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Apr 2024 — SOU EXTENSION 2 GRANTED